Neurology and Neurosurgery - Global Neurology Academy

1-16 of 41

When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic AD
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic AD
CME/CE Virtual Event
When “Mild” Matters Most: Closing Clinical Gaps in Early Symptomatic AD
June 03, 2026
06:00 PM - 07:00 PM CEST
1.00 credit
CME/CE In-Person Event
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
June 15, 2026
Chicago, Illinois
1.50 credits
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
CME/CE Virtual Event
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
June 15, 2026
07:30 AM - 09:00 AM ET
1.50 credits
CME/CE In-Person & Virtual Event
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
Orlando, Florida
1.00 credit
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
CME/CE Virtual Event
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
11:45 AM - 12:45 PM ET
CME/CE In-Person Event
Redefining gMG Management: FcRn Antagonists and the New Era of Precision Neurology
September 30, 2026
Orlando, Florida
CME/CE In-Person & Virtual Event
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
June 15, 2026
Chicago, Illinois
1.50 credits
Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
CME/CE
Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition
Mukul Sharma, MD, MSc, FRCPC; Ashkan Shoamanesh, MD, MSc, FRCPC
0.75 credits
- Mukul Sharma, MD, MSc, FRCPC
- Ashkan Shoamanesh, MD, MSc, FRCPC
0.75 credits
FXIa Remix! Keeping the Flow Without Missing a Beat
FXIa Remix! Keeping the Flow Without Missing a Beat
CME/CE
FXIa Remix! Keeping the Flow Without Missing a Beat
Mike Sharma, MD, MSc, FRCPC; Ashkan Shoamanesh, MD
0.50 credits
- Mike Sharma, MD, MSc, FRCPC
- Ashkan Shoamanesh, MD
- Brian Mac Grory, MB, BCh BAO, MRCP, FAHA, FANA
0.50 credits
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
MinuteCE®
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Christyn Edmundson, MD
1.00 program credit
- Christyn Edmundson, MD
1.00 program credit
Practical Perspectives in Myasthenia Gravis # 1: Diagnostic Logistics—Navigating Complexity Across Ages
Practical Perspectives in Myasthenia Gravis # 1: Diagnostic Logistics—Navigating Complexity Across Ages
CME/CE
Practical Perspectives in Myasthenia Gravis # 1: Diagnostic Logistics—Navigating Complexity Across Ages
Diana Castro, MD; Jonathan Strober, MD
0.25 credits
- Diana Castro, MD
- Jonathan Strober, MD
0.25 credits
Practical Perspectives in Myasthenia Gravis #2: Patient Stratification and Antibody Profiling—Personalizing the Disease Lens
Practical Perspectives in Myasthenia Gravis #2: Patient Stratification and Antibody Profiling—Personalizing the Disease Lens
CME/CE
Practical Perspectives in Myasthenia Gravis #2: Patient Stratification and Antibody Profiling—Personalizing the Disease Lens
Diana Castro, MD; Jonathan Strober, MD
0.25 credits
- Diana Castro, MD
- Jonathan Strober, MD
0.25 credits
Practical Perspectives in Myasthenia Gravis #3: Therapeutic Selection and Monitoring Efficacy—Matching Mechanisms to Patients
Practical Perspectives in Myasthenia Gravis #3: Therapeutic Selection and Monitoring Efficacy—Matching Mechanisms to Patients
CME/CE
Practical Perspectives in Myasthenia Gravis #3: Therapeutic Selection and Monitoring Efficacy—Matching Mechanisms to Patients
Diana Castro, MD; Jonathan Strober, MD
0.25 credits
- Diana Castro, MD
- Jonathan Strober, MD
0.25 credits
Primary Care for the Brain: Prevention and Early Detection of Cognitive Decline
Primary Care for the Brain: Prevention and Early Detection of Cognitive Decline
CME/CE
Primary Care for the Brain: Prevention and Early Detection of Cognitive Decline
Emily D. Clark, DO; Tracey M. Piparo, PA-C, CAQ-PMHC, DFAAPA
1.00 credit
- Emily D. Clark, DO
- Tracey M. Piparo, PA-C, CAQ-PMHC, DFAAPA
- Susan Scanland, MSN, CRNP, GNP-BC, CDP
- Anthony J. Viera, MD, MPH
1.00 credit
New Pathways in the Treatment of DMD
New Pathways in the Treatment of DMD
CME/CE
New Pathways in the Treatment of DMD
Erika Finanger, MD, MS; Aravindhan Veerapandiyan, MD
1.00 credit
- Erika Finanger, MD, MS
- Aravindhan Veerapandiyan, MD
1.00 credit
Implementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis
Implementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis
CME/CE
Implementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis
Pushpa Narayanaswami, MD, FAAN
0.50 credits
- Pushpa Narayanaswami, MD, FAAN
0.50 credits

Prev
1
2
3
Next

1/3